Literature DB >> 4426048

Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma.

C D Buckner, R Briggs, R A Clift, A Fefer, D D Funk, H Glucksberg, P E Neiman, R Storb, E D Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4426048

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  6 in total

Review 1.  Chemotherapy in lung cancer.

Authors:  C G Price; M L Slevin
Journal:  Postgrad Med J       Date:  1989-05       Impact factor: 2.401

2.  High-dose cyclophosphamide with autologous marrow transplantation as initial treatment of small cell carcinoma of the bronchus.

Authors:  R L Souhami; P G Harper; D Linch; C Trask; A H Goldstone; J Tobias; S G Spiro; D M Geddes; J D Richards
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  High-dose cyclophosphamide followed by cisplatinum in the treatment of ovarian cancer.

Authors:  R Osborne; B Evans; C Gallagher; C Wood; M Slevin; J Shepherd; E Wiltshaw
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Intensive chemotherapy for solid tumours--current clinical applications.

Authors:  S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  Cyclophosphamide cardiotoxicity.

Authors:  G von Bernuth; D Adam; R Hofstetter; D Lang; W Mohr; E Kohne; D Niethammer
Journal:  Eur J Pediatr       Date:  1980-06       Impact factor: 3.183

6.  Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule.

Authors:  B D Evans; I E Smith; R D Clutterbuck; J L Millar
Journal:  Br J Cancer       Date:  1984-01       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.